Joe Jimenez and Mark Fishman sign up their 5th drug candidate — and they have another big target in their crosshairs

John Carroll

Editor & Founder

Ex-Novartis chief Joe Jimenez and his longtime colleague Mark Fishman have now ramped up their 5th biotech sub at the upstart Aditum. And once again …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Joe Jimenez and Mark Fishman sign up their 5th drug candidate — and they have another big target in their crosshairs

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Joe Jimenez and Mark Fish­man sign up their 5th drug can­di­date — and they have an­oth­er big tar­get in their crosshairs

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Joe Jimenez and Mark Fishman sign up their 5th drug candidate — and they have another big target in their crosshairs